RE:Simply Wall Street determines ONCY fair value at $157 p/son a NPV of $ 8 billion US for ONCY in the mBC indication by itself. Their analysis did not take into consideration either the pancreatic or the colorectal cancer indications. Nor did they take into consideration pelareorep's application in combination with CAR-T, bispecifics or small molecules such as PARP and CDK4/6 inhibitors in multiple other cancer indications.
So USD 12-15 Bln is not out of the question for ONCY, given the number of cancers and the drug combinations that pelareorep can be part of creating.
Just sayn" ... contrary to those pushing their view of free speech